Europe’s VC Retreat May Threaten Drug Innovation There
This article was originally published in The Pink Sheet Daily
The number of VC firms actively investing in European biotech and life science companies - and the funds available for investing - could fall below the critical mass considered vital for supporting innovation, investors warn.
You may also be interested in...
The Paris-based start-up has raised €32 million from venture investors to address two orphan eye disorders, taking advantage of new research and manufacturing techniques in gene therapy.
French drug delivery company, Adocia, raises $33 million to develop new formulations of therapeutic proteins for wound healing, diabetes
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.